Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma

Benjamin R. Kipp, Jesse S. Voss, Sarah E. Kerr, Emily G. Barr Fritcher, Rondell Graham, Lizhi Zhang, W Edward Jr. Highsmith, Jun Zhang, Lewis Rowland Roberts, Gregory James Gores, Kevin C. Halling

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

Somatic mutations in isocitrate dehydrogenase 1 and 2 genes are common in gliomas and help stratify patients with brain cancer into histologic and molecular subtypes. However, these mutations are considered rare in other solid tumors. The aims of this study were to determine the frequency of isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma and to assess histopathologic differences between specimens with and without an isocitrate dehydrogenase mutation. We sequenced 94 formalin-fixed, paraffin-embedded cholangiocarcinoma (67 intrahepatic and 27 extrahepatic) assessing for isocitrate dehydrogenase 1 (codon 132) and isocitrate dehydrogenase 2 (codons 140 and 172) mutations. Multiple histopathologic characteristics were also evaluated and compared with isocitrate dehydrogenase 1/2 mutation status. Of the 94 evaluated specimens, 21 (22%) had a mutation including 14 isocitrate dehydrogenase 1 and 7 isocitrate dehydrogenase 2 mutations. Isocitrate dehydrogenase mutations were more frequently observed in intrahepatic cholangiocarcinoma than in extrahepatic cholangiocarcinoma (28% versus 7%, respectively; P =.030). The 14 isocitrate dehydrogenase 1 mutations were R132C (n = 9), R132S (n = 2), R132G (n = 2), and R132L (n = 1). The 7 isocitrate dehydrogenase 2 mutations were R172K (n = 5), R172M (n = 1), and R172G (n = 1). Isocitrate dehydrogenase mutations were more frequently observed in tumors with clear cell change (P <.001) and poorly differentiated histology (P =.012). The results of this study show for the first time that isocitrate dehydrogenase 1 and 2 genes are mutated in cholangiocarcinoma. The results of this study are encouraging because it identifies a new potential target for genotype-directed therapeutic trials and may represent a potential biomarker for earlier detection of cholangiocarcinoma in a subset of cases.

Original languageEnglish (US)
Pages (from-to)1552-1558
Number of pages7
JournalHuman Pathology
Volume43
Issue number10
DOIs
StatePublished - Oct 2012

Fingerprint

Isocitrate Dehydrogenase
Cholangiocarcinoma
Mutation
Codon
Brain Neoplasms
Glioma
Paraffin
Formaldehyde
Genes

Keywords

  • 2-hydroxyglutarate
  • Bile duct
  • Biliary tract
  • Cholangiocarcinoma
  • Isocitrate dehydrogenase

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Kipp, B. R., Voss, J. S., Kerr, S. E., Barr Fritcher, E. G., Graham, R., Zhang, L., ... Halling, K. C. (2012). Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Human Pathology, 43(10), 1552-1558. https://doi.org/10.1016/j.humpath.2011.12.007

Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. / Kipp, Benjamin R.; Voss, Jesse S.; Kerr, Sarah E.; Barr Fritcher, Emily G.; Graham, Rondell; Zhang, Lizhi; Highsmith, W Edward Jr.; Zhang, Jun; Roberts, Lewis Rowland; Gores, Gregory James; Halling, Kevin C.

In: Human Pathology, Vol. 43, No. 10, 10.2012, p. 1552-1558.

Research output: Contribution to journalArticle

Kipp, BR, Voss, JS, Kerr, SE, Barr Fritcher, EG, Graham, R, Zhang, L, Highsmith, WEJ, Zhang, J, Roberts, LR, Gores, GJ & Halling, KC 2012, 'Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma', Human Pathology, vol. 43, no. 10, pp. 1552-1558. https://doi.org/10.1016/j.humpath.2011.12.007
Kipp, Benjamin R. ; Voss, Jesse S. ; Kerr, Sarah E. ; Barr Fritcher, Emily G. ; Graham, Rondell ; Zhang, Lizhi ; Highsmith, W Edward Jr. ; Zhang, Jun ; Roberts, Lewis Rowland ; Gores, Gregory James ; Halling, Kevin C. / Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. In: Human Pathology. 2012 ; Vol. 43, No. 10. pp. 1552-1558.
@article{6a5f55c7b96f4a3ab3ffe2b634298deb,
title = "Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma",
abstract = "Somatic mutations in isocitrate dehydrogenase 1 and 2 genes are common in gliomas and help stratify patients with brain cancer into histologic and molecular subtypes. However, these mutations are considered rare in other solid tumors. The aims of this study were to determine the frequency of isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma and to assess histopathologic differences between specimens with and without an isocitrate dehydrogenase mutation. We sequenced 94 formalin-fixed, paraffin-embedded cholangiocarcinoma (67 intrahepatic and 27 extrahepatic) assessing for isocitrate dehydrogenase 1 (codon 132) and isocitrate dehydrogenase 2 (codons 140 and 172) mutations. Multiple histopathologic characteristics were also evaluated and compared with isocitrate dehydrogenase 1/2 mutation status. Of the 94 evaluated specimens, 21 (22{\%}) had a mutation including 14 isocitrate dehydrogenase 1 and 7 isocitrate dehydrogenase 2 mutations. Isocitrate dehydrogenase mutations were more frequently observed in intrahepatic cholangiocarcinoma than in extrahepatic cholangiocarcinoma (28{\%} versus 7{\%}, respectively; P =.030). The 14 isocitrate dehydrogenase 1 mutations were R132C (n = 9), R132S (n = 2), R132G (n = 2), and R132L (n = 1). The 7 isocitrate dehydrogenase 2 mutations were R172K (n = 5), R172M (n = 1), and R172G (n = 1). Isocitrate dehydrogenase mutations were more frequently observed in tumors with clear cell change (P <.001) and poorly differentiated histology (P =.012). The results of this study show for the first time that isocitrate dehydrogenase 1 and 2 genes are mutated in cholangiocarcinoma. The results of this study are encouraging because it identifies a new potential target for genotype-directed therapeutic trials and may represent a potential biomarker for earlier detection of cholangiocarcinoma in a subset of cases.",
keywords = "2-hydroxyglutarate, Bile duct, Biliary tract, Cholangiocarcinoma, Isocitrate dehydrogenase",
author = "Kipp, {Benjamin R.} and Voss, {Jesse S.} and Kerr, {Sarah E.} and {Barr Fritcher}, {Emily G.} and Rondell Graham and Lizhi Zhang and Highsmith, {W Edward Jr.} and Jun Zhang and Roberts, {Lewis Rowland} and Gores, {Gregory James} and Halling, {Kevin C.}",
year = "2012",
month = "10",
doi = "10.1016/j.humpath.2011.12.007",
language = "English (US)",
volume = "43",
pages = "1552--1558",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "10",

}

TY - JOUR

T1 - Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma

AU - Kipp, Benjamin R.

AU - Voss, Jesse S.

AU - Kerr, Sarah E.

AU - Barr Fritcher, Emily G.

AU - Graham, Rondell

AU - Zhang, Lizhi

AU - Highsmith, W Edward Jr.

AU - Zhang, Jun

AU - Roberts, Lewis Rowland

AU - Gores, Gregory James

AU - Halling, Kevin C.

PY - 2012/10

Y1 - 2012/10

N2 - Somatic mutations in isocitrate dehydrogenase 1 and 2 genes are common in gliomas and help stratify patients with brain cancer into histologic and molecular subtypes. However, these mutations are considered rare in other solid tumors. The aims of this study were to determine the frequency of isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma and to assess histopathologic differences between specimens with and without an isocitrate dehydrogenase mutation. We sequenced 94 formalin-fixed, paraffin-embedded cholangiocarcinoma (67 intrahepatic and 27 extrahepatic) assessing for isocitrate dehydrogenase 1 (codon 132) and isocitrate dehydrogenase 2 (codons 140 and 172) mutations. Multiple histopathologic characteristics were also evaluated and compared with isocitrate dehydrogenase 1/2 mutation status. Of the 94 evaluated specimens, 21 (22%) had a mutation including 14 isocitrate dehydrogenase 1 and 7 isocitrate dehydrogenase 2 mutations. Isocitrate dehydrogenase mutations were more frequently observed in intrahepatic cholangiocarcinoma than in extrahepatic cholangiocarcinoma (28% versus 7%, respectively; P =.030). The 14 isocitrate dehydrogenase 1 mutations were R132C (n = 9), R132S (n = 2), R132G (n = 2), and R132L (n = 1). The 7 isocitrate dehydrogenase 2 mutations were R172K (n = 5), R172M (n = 1), and R172G (n = 1). Isocitrate dehydrogenase mutations were more frequently observed in tumors with clear cell change (P <.001) and poorly differentiated histology (P =.012). The results of this study show for the first time that isocitrate dehydrogenase 1 and 2 genes are mutated in cholangiocarcinoma. The results of this study are encouraging because it identifies a new potential target for genotype-directed therapeutic trials and may represent a potential biomarker for earlier detection of cholangiocarcinoma in a subset of cases.

AB - Somatic mutations in isocitrate dehydrogenase 1 and 2 genes are common in gliomas and help stratify patients with brain cancer into histologic and molecular subtypes. However, these mutations are considered rare in other solid tumors. The aims of this study were to determine the frequency of isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma and to assess histopathologic differences between specimens with and without an isocitrate dehydrogenase mutation. We sequenced 94 formalin-fixed, paraffin-embedded cholangiocarcinoma (67 intrahepatic and 27 extrahepatic) assessing for isocitrate dehydrogenase 1 (codon 132) and isocitrate dehydrogenase 2 (codons 140 and 172) mutations. Multiple histopathologic characteristics were also evaluated and compared with isocitrate dehydrogenase 1/2 mutation status. Of the 94 evaluated specimens, 21 (22%) had a mutation including 14 isocitrate dehydrogenase 1 and 7 isocitrate dehydrogenase 2 mutations. Isocitrate dehydrogenase mutations were more frequently observed in intrahepatic cholangiocarcinoma than in extrahepatic cholangiocarcinoma (28% versus 7%, respectively; P =.030). The 14 isocitrate dehydrogenase 1 mutations were R132C (n = 9), R132S (n = 2), R132G (n = 2), and R132L (n = 1). The 7 isocitrate dehydrogenase 2 mutations were R172K (n = 5), R172M (n = 1), and R172G (n = 1). Isocitrate dehydrogenase mutations were more frequently observed in tumors with clear cell change (P <.001) and poorly differentiated histology (P =.012). The results of this study show for the first time that isocitrate dehydrogenase 1 and 2 genes are mutated in cholangiocarcinoma. The results of this study are encouraging because it identifies a new potential target for genotype-directed therapeutic trials and may represent a potential biomarker for earlier detection of cholangiocarcinoma in a subset of cases.

KW - 2-hydroxyglutarate

KW - Bile duct

KW - Biliary tract

KW - Cholangiocarcinoma

KW - Isocitrate dehydrogenase

UR - http://www.scopus.com/inward/record.url?scp=84866504465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866504465&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2011.12.007

DO - 10.1016/j.humpath.2011.12.007

M3 - Article

C2 - 22503487

AN - SCOPUS:84866504465

VL - 43

SP - 1552

EP - 1558

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 10

ER -